Gemcitabine, Cisplatin

DRUG14 trials

Sponsors

National Taiwan University Hospital, Samsung Medical Center, Spanish Lung Cancer Group, Gyeongsang National University Hospital, Southwest Hospital, China

Conditions

BRCA1 MutationBile Duct CarcinomaBiliary Tract CancerBladder CancerBorderline ResectableBreast CancerCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell

Phase 1

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

RecruitingNCT06802835

Sun Yat-sen UniversityMetastatic Nasopharyngeal Carcinoma, Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma

Start: 2025-05-31End: 2029-02-20Target: 148Updated: 2025-05-16

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

RecruitingNCT06916494

First Affiliated Hospital of Chongqing Medical UniversityMuscle Invasive Bladder Cancer

Start: 2025-05-01End: 2026-01-20Target: 10Updated: 2025-04-10

Phase 2

Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00173888

National Taiwan University HospitalNon-small Cell Lung Cancer

Start: 2003-07-31End: 2012-11-30Updated: 2012-12-06

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

TerminatedNCT01096745

Gyeongsang National University HospitalLocally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer

Start: 2010-07-31End: 2013-09-30Target: 78Updated: 2011-06-23

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

CompletedNCT03051373

Chinese PLA General HospitalCarcinoma, Transitional Cell

Start: 2017-04-01End: 2020-04-30Updated: 2021-08-09

Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma

Not yet recruitingNCT06923475

Amsterdam UMC, location VUmcBorderline Resectable, Distal Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma +2

Start: 2025-05-05End: 2028-11-06Target: 150Updated: 2025-04-11

Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma

Not yet recruitingNCT06927128

Changhai HospitalNAC, UTUC

Start: 2025-05-15End: 2028-06-15Target: 45Updated: 2025-04-15

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

RecruitingNCT07025174

First Affiliated Hospital of Zhejiang UniversityBile Duct Carcinoma, Biliary Tract Cancer, Cholangiocarcinoma +1

Start: 2025-06-01End: 2027-12-31Target: 60Updated: 2025-06-17

Phase 3

Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

WithdrawnNCT00329472

Samsung Medical CenterCarcinoma, Non-Small-Cell Lung

Start: 2006-04-30End: 2010-07-31Updated: 2010-08-27

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

TerminatedNCT00617656

Spanish Lung Cancer GroupBRCA1 Mutation, Non Small Cell Lung Cancer

Start: 2008-02-29End: 2015-04-30Updated: 2024-01-30

Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer

Southwest Hospital, ChinaBladder Cancer

Start: 2014-03-31End: 2019-04-30Target: 200Updated: 2014-02-28

ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

CompletedNCT02546934

Fudan UniversityBreast Cancer

Start: 2016-03-31End: 2020-04-30Target: 254Updated: 2022-04-22

GNT Induction Treatment in Locally Advanced NPC

RecruitingNCT06026878

Air Force Military Medical University, ChinaNasopharyngeal Carcinoma

Start: 2023-09-01End: 2027-09-30Target: 228Updated: 2023-09-07

Unknown Phase

Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer

The First Affiliated Hospital with Nanjing Medical UniversityBladder Cancer, Epirubicin Instillation, Gemcitabine and Cisplatin Chemotherapy +2

Start: 2016-01-31End: 2020-12-31Target: 208Updated: 2016-03-24

Related Papers

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.

2022-07-1252 citations

<p>Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method</p>

Cancer Management and Research2019-07-015 citations

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.

2019-03-054 citations

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

2018-11-2213 citations

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

2014-08-2719 citations

Treatment Based on BRCA1 and RAP80 Does Not Extend PFS

MD Conference Express2013-07-01

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

Journal of Clinical Oncology2013-06-205 citations

Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).

2013-06-011 citations